Carlos Ramirez

Cooley advised Uber Technologies, a technology platform that uses a massive network, top technology, operational excellence and product expertise to power movement from Point A to Point B, on its $4 billion investment-grade bond offering.

Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.

Cooley advised Structure Therapeutics (Nasdaq: GPCR), a global, clinical-stage biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, on its upsized $547.4 million underwritten public offering.

Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.

Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.